MedTrace Logo

Do Elevated BNP Levels Predict Hemodynamically Significant PDAs

NCT01497054 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2013-07-04

No results posted yet for this study

Summary

The purpose of this study is to determine if B type natriuretic peptide (BNP) levels can be used to predict a hemodynamically significant patent ductus arteriosus (PDA). This peptide is produced by the ventricles in the heart when they are under stress, such as when a ductus remains open. If we can use a simple and inexpensive blood test to determine whether a PDA needs to be treated, we can potentially treat infants sooner than if they needed to wait for the availability of a cardiologist to perform an echocardiogram. This might decrease some of the deleterious effects of PDAs on the preterm infant such as bronchopulmonary dysplasia, necrotizing enterocolitis, renal hypoperfusion, and pulmonary hemorrhage. In a situation where follow up echocardiogram after a course of medical therapy shows persistent PDA, this test may help to decide whether this baby needs further treatment, either medical or surgical.

Conditions

  • Patent Ductus Arteriosus

Sponsors & Collaborators

  • Alere, Inc.

    collaborator INDUSTRY

  • Albany Medical College

    lead OTHER

Principal Investigators

  • Kate A Tauber, MD · Albany Medical College

  • Upender K Munshi, MD · Albany Medical College

  • Robin Doyle, MD · Capital Distric Pediatric Cardiology, affiliated with Albany Medical Center

Eligibility

Min Age
1 Hour
Max Age
24 Hours
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01497054 on ClinicalTrials.gov